文献速递头颈外科

老年局部晚期头颈癌放疗联合西妥昔单抗或顺铂的医疗价值评估

Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2019-01-01

该队列研究基于SEER-Medicare数据库(2004-2014年),纳入1091例65岁以上局部晚期头颈癌患者,比较单纯放疗、放疗联合顺铂或西妥昔单抗的生存、急诊/住院率及90天花费。结果显示,放疗联合顺铂较单纯放疗生存更优(HR 0.64),但急诊和住院率更高;放疗联合西妥昔单抗较单纯放疗无生存差异,急诊率更高且花费更高。提示对于老年体弱患者,单纯放疗仍应作为新型疗法的对照臂。

要点

  • 放疗联合顺铂较单纯放疗改善总生存(HR 0.64),但增加急诊和住院率。
  • 放疗联合西妥昔单抗较单纯放疗无生存获益,急诊率更高且花费更高。
  • 老年局部晚期头颈癌患者中,单纯放疗仍应作为评估新疗法的治疗臂。

核心结论

  • 在老年局部晚期头颈癌患者中,放疗联合西妥昔单抗较单纯放疗无生存差异,但急诊就诊率更高且花费更高。
  • 放疗联合顺铂较单纯放疗改善总生存,但急诊和住院率更高。
  • 研究提示单纯放疗应维持在老年及体弱患者新型疗法评估的治疗臂中。

研究设计与样本

  • 队列研究,数据来自SEER-Medicare数据库2004年1月1日至2014年12月31日的记录。
  • 纳入65岁及以上、2006-2013年诊断的III-IVB期头颈癌患者,仅1种癌症记录且未接受手术。
  • 共纳入1091例患者,其中815例(74.7%)为男性,平均年龄73.9岁(SD 6.6)。

主要发现

  • 放疗联合顺铂组较单纯放疗组总生存更高(调整HR 0.64;95%CI 0.47-0.87)。
  • 放疗联合西妥昔单抗组较单纯放疗组总生存无差异(调整HR 0.95;95%CI 0.75-1.20)。
  • 放疗联合顺铂组较单纯放疗组90天内急诊就诊率(调整IRR 1.72;95%CI 1.30-2.30)和住院率(调整IRR 1.48;95%CI 1.12-1.98)更高。
  • 放疗联合西妥昔单抗组较单纯放疗组90天内急诊就诊率更高(调整IRR 1.38;95%CI 1.05-1.82)。
  • 放疗联合西妥昔单抗组90天治疗开始后花费为48 620美元(95%CI 46 466-50 775),高于放疗联合顺铂组的33 009美元(95%CI 31 499-34 519)和单纯放疗组的27 622美元(95%CI 25 118-30 126)。

临床怎么用

  • 对于老年局部晚期头颈癌患者,选择放疗联合西妥昔单抗时需权衡其无生存获益且花费更高的特点。
  • 放疗联合顺铂虽改善生存但增加急诊和住院风险,应加强不良反应监测和支持治疗。
  • 在老年及体弱患者的新型疗法临床试验中,单纯放疗仍应作为对照臂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinicians frequently use radiotherapy with cetuximab over radiotherapy only or radiotherapy with cisplatin because of a perceived survival and tolerability advantage, but scant data are available to support this perception. OBJECTIVE: To measure the 3 aspects of value (quality, outcomes, and cost) in older patients receiving radiotherapy only, radiotherapy with cisplatin, or radiotherapy with cetuximab for locoregionally advanced head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: For this cohort study, patient records were obtained from the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare outcomes and claims database from January 1, 2004, to December 31, 2014. Participants were 65 years or older; received a diagnosis between 2006 and 2013 of stages III to IVB head and neck cancer; had only 1 cancer on record; and did not undergo surgical intervention. Data analysis was conducted from February 5, 2018, to March 27, 2019. EXPOSURES: Patients were divided into exposure arms on the basis of their first-line therapy or identified chemoradiotherapy and radiotherapy regimen. MAIN OUTCOMES AND MEASURES: Overall survival was analyzed by propensity score matching Cox proportional hazards regression models, quality by measuring 90-day emergency department (ED) visit and inpatient admission rates, and costs by assessing 90-day total Medicare spending. RESULTS: The overall cohort included 1091 patients, of whom 815 (74.7%) were male; the mean (SD) age was 73.9 (6.6) years. Patients receiving radiotherapy with cisplatin had higher overall survival compared with those receiving radiotherapy only (adjusted hazard ratio [HR], 0.64; 95% CI, 0.47-0.87). This finding was not seen in patients receiving radiotherapy with cetuximab (adjusted HR, 0.95; 95% CI, 0.75-1.20), compared with the radiotherapy only group, and it persisted after stratifying patients by age. The ED visit (adjusted incidence rate ratio [IRR], 1.72; 95% CI, 1.30-2.30) and inpatient admission (adjusted IRR, 1.48; 95% CI, 1.12-1.98) rates in the 90 days after treatment start were higher in patients receiving radiotherapy with cisplatin compared with those treated with radiotherapy only. Patients receiving radiotherapy with cetuximab had a higher rate of ED visits (adjusted IRR, 1.38; 95% CI, 1.05-1.82) compared with those in the radiotherapy only group. The 90-day after-treatment spending for patients receiving radiotherapy with cetuximab was $48 620 (95% CI, $46 466-$50 775) compared with $33 009 (95% CI, $31 499-$34 519) for radiotherapy with cisplatin and $27 622 (95% CI, $25 118-$30 126) for radiotherapy only. CONCLUSIONS AND RELEVANCE: In this cohort study, no survival difference, a higher rate of ED visits but not of inpatient admissions, and higher spending were observed in patients receiving radiotherapy with cetuximab compared with patients receiving radiotherapy only. The findings suggest that radiotherapy alone should be maintained as a treatment arm in evaluation of novel therapeutics for locoregionally advanced head and neck cancer in older and sicker patients.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Saraswathula A, Chen MM, Colevas AD, et al. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31621810. doi:10.1001/jamaoto.2019.2381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。